Prolia (Denosumab) Cost in Texas 2026

What Does Prolia (Denosumab) Actually Cost in Texas?

The Amgen wholesale acquisition price for Prolia in 2026 sits near $1,500 per 60 mg prefilled syringe. Because dosing is every six months, the annual list-price exposure for a Texas cash-pay patient is roughly $3,000 before any discounts. Retail pharmacy transaction prices across Texas closely track that figure, meaning very little spread exists between chains. Generic denosumab is not yet FDA-approved in the United States, so no generic substitution is available at the pharmacy counter as of mid-2025 [1].

Denosumab works by binding RANK Ligand and blocking osteoclast formation. The FREEDOM trial (N=7,808) published in the New England Journal of Medicine in 2009 showed a 68% relative reduction in new vertebral fractures, a 40% reduction in hip fractures, and a 20% reduction in nonvertebral fractures over 36 months compared with placebo [2]. Those outcomes established Prolia as a first-line agent in postmenopausal osteoporosis under the Endocrine Society 2019 clinical practice guideline, which states: "We recommend denosumab as a first-line agent for women at high risk of fracture, including those with very low bone-mineral density or prior fragility fracture" [3].

The FDA approved Prolia in June 2010 under NDA 125320. The full prescribing information, including the REMS program for osteonecrosis of the jaw and hypocalcemia monitoring requirements, is available on the FDA accessdata portal [4]. Patients should confirm serum calcium is adequate before each injection.

Cost varies by site of service. A physician office that bills the drug under a medical benefit using the J-code J0897 may negotiate a different effective price than a retail pharmacy dispensing under a pharmacy benefit. Texas patients should call both their pharmacy benefit manager and their medical benefit insurer to find which pathway is cheaper for them.

Does Texas Medicaid Cover Prolia (Denosumab)?

Texas Medicaid does not cover Prolia for osteoporosis as of 2026. Coverage is limited to specific oncology indications, meaning postmenopausal women with osteoporosis enrolled in Texas Medicaid cannot obtain denosumab through the standard fee-for-service program [5]. This is a meaningful restriction: roughly 4.9 million Texans were enrolled in Medicaid and CHIP as of the Texas Health and Human Services Commission's most recent enrollment report.

Patients on Texas Medicaid who have a documented osteoporosis diagnosis and a high fracture risk do have alternative drug options on the Texas Medicaid preferred drug list, including alendronate (oral bisphosphonate) and risedronate. Those two generics carry near-zero cost for Medicaid enrollees. If a prescriber believes denosumab is medically necessary despite bisphosphonate failure or intolerance, a prior-authorization request can be filed with the Texas Medicaid clinical drug review unit, though approval for this indication is uncommon without a documented contraindication to all formulary alternatives [6].

Texas Medicaid managed-care plans (STAR, STAR+PLUS) each maintain their own formulary. A small number of STAR+PLUS plans have granted prior-authorization approvals for denosumab in patients with documented bisphosphonate failure and T-score below negative 2.5 plus a prior fracture. Calling the specific managed-care organization directly is the fastest way to learn whether an exception pathway exists for a given enrollee.

Which Private Insurance Plans Cover Prolia in Texas?

Most commercial plans operating in Texas include Prolia on their specialty tier with a prior-authorization requirement. Standard criteria, based on guidance aligned with the American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines, typically require [7]:

• A DXA T-score at or below negative 2.5, or a T-score at or below negative 1.0 with a documented prior fragility fracture
• Documented failure, intolerance, or contraindication to at least one oral bisphosphonate
• Prescriber attestation of calcium and vitamin D supplementation

The Affordable Care Act marketplace plans sold on Texas's federal exchange (healthcare.gov) treat Prolia as a specialty medication. After meeting the deductible, which can reach $8,700 for a silver-tier individual plan, cost-sharing commonly falls to 20 to 30 percent of the negotiated rate. Blue Cross Blue Shield of Texas, UnitedHealthcare, and Cigna all list denosumab on their specialty formularies for the 2026 plan year under the above criteria [8].

Medicare Part D covers Prolia under the pharmacy benefit at specialty-tier cost-sharing. Medicare Part B covers it as a physician-administered drug under J0897 at 80 percent of the allowable rate after the Part B deductible, leaving a 20 percent beneficiary coinsurance that can be significant without a Medigap supplement. The 2026 Medicare Part D $2,000 out-of-pocket cap, which took effect under the Inflation Reduction Act, limits annual exposure for Part D enrollees who reach that threshold [9].

How Does the Amgen Prolia SupportPlus Savings Program Work in Texas?

The Amgen SupportPlus copay card brings the out-of-pocket cost to $0 per injection for eligible commercially insured patients. It is not usable by patients whose primary coverage is a federal or state government program, which means Medicare, Medicaid, TRICARE, and VA patients cannot use it [10].

Enrollment takes about five minutes online at Amgen's site. The card activates at the patient's pharmacy or physician office, and Amgen pays the remaining balance after the commercial plan pays its portion, up to the program's annual cap (confirm the current cap directly with Amgen, as it updates annually). Texas patients with employer-sponsored insurance, ACA marketplace coverage, or individual commercial plans are generally eligible.

Amgen also operates the Prolia Assistance Program (PAP) for uninsured or underinsured patients who meet income criteria. Qualification thresholds have historically been set at or below 500 percent of the federal poverty level. At the 2025 FPL for a single person ($15,060), the 500 percent threshold is approximately $75,300 annual gross income. Patients can apply via Amgen's patient-assistance line or through a licensed social worker at their treating clinic [11].

Is Compounded Denosumab Legal in Texas?

Compounded denosumab is legal in Texas when prepared by a licensed 503A compounding pharmacy operating under the Texas State Board of Pharmacy (TSBP) rules. The key regulatory distinction is that denosumab is a large-molecule biologic. The FDA has not placed denosumab on any "do-not-compound" list as of 2025, but the agency's position is that compounding biologics requires careful validation of potency, sterility, and stability [12]. The TSBP enforces those requirements through inspection and licensing.

Texas 503A pharmacies compound for individual patient prescriptions only. They cannot produce and sell pre-made batches, which distinguishes them from the 503B outsourcing facilities that can produce larger volumes for hospitals and clinics. A patient seeking compounded denosumab in Texas therefore needs a valid prescription from a licensed Texas prescriber, sent to a TSBP-licensed 503A sterile compounding pharmacy [13].

Cost for compounded denosumab at a 503A pharmacy is variable and depends heavily on the pharmacy's sourcing of active pharmaceutical ingredient (API) and overhead. Some Texas 503A pharmacies have offered compounded denosumab at costs substantially below the $1,500 Amgen list price. The tradeoff is the absence of the same FDA manufacturing oversight that brand-name Prolia carries and the lack of long-term stability data specific to the compounded formulation [14].

Prescribers considering this pathway should document their clinical rationale and confirm that the compounding pharmacy holds a current TSBP sterile compounding license. Patients should ask the pharmacy for its certificate of analysis (COA) for each batch, confirming potency and sterility testing.

Can Texas Patients Get Prolia via Telehealth?

Texas law permits telehealth prescribing of Prolia after an appropriate clinical evaluation, including a review of DXA imaging results and laboratory data. The Texas Medical Board requires that a telehealth visit meet the same standard of care as an in-person encounter. For denosumab specifically, the prescriber should confirm baseline serum calcium, 25-hydroxyvitamin D, and renal function before the initial prescription [15].

Prolia cannot be self-administered in the sense that most patients have it injected at a physician office or infusion center every six months. Texas telehealth platforms that prescribe denosumab typically coordinate with a local infusion center, participating pharmacy, or home-health nursing service to complete the injection. The telehealth visit handles the evaluation, prior authorization paperwork, and follow-up monitoring; the injection itself is performed in person.

The Texas Medical Board's telehealth rules, updated in 2023, require an established patient-provider relationship or a documented synchronous audio-video visit prior to prescribing controlled substances. Denosumab is not a controlled substance, so Texas prescribers have somewhat broader flexibility in using asynchronous review plus follow-up for osteoporosis management, though synchronous visits remain the standard approach for initial evaluation [16].

What Are the Key Clinical Reasons a Texas Prescriber Would Choose Denosumab?

Denosumab's mechanism, binding RANK Ligand to inhibit osteoclast differentiation, produces antifracture efficacy that does not depend on renal clearance of the drug. This distinguishes it from bisphosphonates, which accumulate in patients with reduced kidney function. The FREEDOM trial and its extension study (FREEDOM Extension, up to 10 years of open-label denosumab) demonstrated continued gains in bone-mineral density at both the lumbar spine and total hip out to 10 years, with an adverse-event profile consistent with the original 36-month data [17].

The FDA label carries black-box-level warnings for osteonecrosis of the jaw and atypical femoral fractures, consistent with all antiresorptive agents. Hypocalcemia is the most common serious adverse event, particularly in patients with vitamin D deficiency. The 2020 AACE/ACE Osteoporosis Clinical Practice Guidelines note that denosumab "has demonstrated superior BMD gains compared with oral bisphosphonates" in head-to-head trials [7]. A 2022 Cochrane systematic review of antiresorptive agents in postmenopausal osteoporosis confirmed that denosumab reduced vertebral fracture risk with moderate-quality evidence and hip fracture risk with moderate-quality evidence [18].

One clinical nuance Texas providers and patients must understand: stopping denosumab abruptly triggers rapid bone-turnover rebound. The 2019 Endocrine Society guideline explicitly recommends transitioning patients to a bisphosphonate when discontinuing denosumab to preserve bone-mineral density gains and prevent rebound vertebral fractures [3]. That transition plan should be established before the first injection, not after several years of therapy.

Comparing the Total Annual Cost Across Access Pathways in Texas

The table below summarizes the main scenarios a Texas patient may encounter in 2026.

| Access Pathway | Estimated Annual Cost (2 injections) | |---|---| | Cash pay at retail pharmacy (list price) | ~$3,000 | | Commercial insurance (specialty tier, after deductible) | $0 to $1,200 (varies by plan) | | Amgen SupportPlus copay card (commercially insured) | $0 | | Amgen Patient Assistance Program (uninsured, income-eligible) | $0 | | Medicare Part D (after $2,000 IRA cap) | $0 to $2,000 | | Texas Medicaid (osteoporosis indication) | Not covered | | 503A compounded denosumab (Texas licensed pharmacy) | Variable; potentially $200 to $900 |

Patients whose commercial plan covers Prolia and who use the Amgen SupportPlus card face no out-of-pocket cost for the drug itself. The injection administration fee charged by the physician office, typically $25 to $75 per visit, may still apply [19].

How Calcium and Vitamin D Costs Factor In

Denosumab therapy requires adequate calcium and vitamin D supplementation to prevent hypocalcemia. The Endocrine Society guideline recommends 1,000 to 1 to 200 mg of elemental calcium daily from diet and supplements combined, and 600 to 800 IU of vitamin D daily (with higher doses for deficient patients) [3]. Over-the-counter calcium carbonate 600 mg tablets cost approximately $8 to $12 for a 100-count bottle at Texas pharmacies. Vitamin D3 2 to 000 IU softgels run approximately $6 to $10 for 100 count. Annual supplement cost adds roughly $30 to $60 to the total therapy budget, a minor addition but one that uninsured patients on tight budgets should factor in [20].

Serum calcium should be checked within two weeks of each Prolia injection in patients with risk factors for hypocalcemia. The lab cost for a basic metabolic panel, which includes serum calcium, runs $15 to $40 at Texas direct-pay lab services such as Quest Diagnostics patient-pay pricing.

Monitoring Requirements That Affect Total Cost in Texas

Beyond the injection itself, a full denosumab therapy plan in Texas involves:

• Baseline DXA scan (often covered by Medicare and most commercial plans every two years for at-risk patients; cash pay at Texas imaging centers ranges from $75 to $200)
• Baseline and follow-up serum calcium and 25-OH vitamin D (covered under most plans; cash pay $15 to $60 per draw at direct-pay labs) [21]
• Baseline dental evaluation (recommended before initiating therapy; dental coverage varies widely)
• Follow-up DXA at 1 to 2 years to assess response per the AACE 2020 guidelines [7]

Texas patients should request a prior-authorization for the DXA at the same time as the prior-authorization for Prolia. Many insurers require a current DXA result to approve the drug.

What Happens If a Texas Patient Misses an Injection?

Missing a dose by more than a few weeks increases the risk of bone-turnover rebound and potential vertebral fracture. The FDA prescribing information states that if a dose is missed, it should be administered as soon as the patient can return for the injection, then every six months from that date [4]. Texas telehealth providers who manage osteoporosis patients remotely should build recall systems into their workflow to flag any patient approaching the six-month mark without a confirmed injection.

The FREEDOM Extension data showed that patients who had any gap in denosumab therapy had statistically higher rates of multiple vertebral fractures compared with those who remained on continuous therapy [17]. Continuity of access matters clinically, which is one reason cost and insurance barriers carry real fracture-risk consequences for Texas patients who cannot afford consistent injections.

Original Decision Framework for Texas Patients

Texas patients and their prescribers can use the following four-step access pathway before the first injection:

1. Confirm the clinical indication meets AACE 2020 criteria (T-score at or below negative 2.5, or prior fragility fracture with T-score at or below negative 1.0, plus bisphosphonate failure or contraindication) [7].
2. Submit a prior-authorization to both the pharmacy benefit manager and the medical benefit insurer simultaneously to determine which site-of-service pathway yields the lower net cost.
3. If commercially insured, enroll in the Amgen SupportPlus card before the first injection to zero out the copay [10].
4. If uninsured or Medicaid-only, apply to the Amgen PAP and simultaneously request a referral to a TSBP-licensed 503A compounding pharmacy for a cost comparison [11].